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ARTICLE OPEN
Item-based analysis of the effects of duloxetine in depression: a
patient-level post hoc study
Alexander Lisinski1, Fredrik Hieronymus 1, Jakob Näslund1, Staffan Nilsson2,3 and Elias Eriksson1
Oft-cited trial-level meta-analyses casting doubt on the usefulness of antidepressants have been based on re-analyses of to what
extent the active drug has outperformed placebo in reducing the sum score of the Hamilton Depression Rating Scale (HDRS-17-
sum) in clinical trials. Recent studies, however, suggest patient-level analyses of individual HDRS items to be more informative when
assessing the efficacy of an antidepressant. To shed further light on both symptom-reducing and symptom-aggravating effects of a
serotonin and noradrenaline reuptake inhibitor, duloxetine, when used for major depression in adults, we hence applied this
approach to re-analyse data from 13 placebo-controlled trials. In addition, using patient-level data from 28 placebo-controlled trials
of selective serotonin reuptake inhibitors (SSRIs), the response profile of duloxetine was compared to that of these drugs.
Duloxetine induced a robust reduction in depressed mood that was not dependent on baseline severity and not caused by side-
effects breaking the blind. A beneficial effect on depressed mood was at hand already after one week; when outcome was assessed
using HDRS-17-sum as effect parameter, this early response was however masked by a concomitant deterioration with respect to
adverse event-related items. No support for a suicide-provoking effect of duloxetine was obtained. The response profile of
duloxetine was strikingly similar to that of the SSRIs. We conclude that the use of HDRS-17-sum as effect parameter underestimates
the true efficacy and masks an early effect of duloxetine on core symptoms of depression. No support for major differences
between duloxetine and SSRIs in clinical profile were obtained.
Neuropsychopharmacology (2020) 45:553–560; https://doi.org/10.1038/s41386-019-0523-4
INTRODUCTION
The ongoing debate regarding the alleged ineffectiveness of
antidepressants has to a large extent been based on trial-based
meta-analyses using the sum score of the 17-item Hamilton
Depression Rating Scale (HDRS-17-sum) as effect parameter [1].
The HDRS-17 has, however, been criticised for shortcomings likely
to reduce the apparent difference between active drug and
placebo: it is multidimensional, it includes items that are often
absent at baseline, it includes non-specific symptoms often
present also in non-depressed patients, and it may be contami-
nated by common antidepressant side effects [2–6]. Thus, in
patient-level analyses comparing selective serotonin reuptake
inhibitors (SSRIs) to placebo with respect to reduction in the first
item of the HDRS-17, depressed mood, a considerably more
consistent and robust superiority of active drug over placebo was
revealed as compared to when HDRS-17-sum was used as effect
parameter [5, 6].
One purpose of the present work was to use patient-level data
to explore if these results can be extended to an antidepressant
with a somewhat different pharmacological profile, the serotonin
and noradrenalin reuptake inhibitor (SNRI) duloxetine [7].
Prompted by claims that a possible effect of antidepressants be
restricted to the most severe cases [1, 8], or be merely the
consequence of side effect breaking the blind in patients [9], these
possibilities were also addressed, as was the issue of to what
extent duloxetine may cause initial anxiety- or suicide-provoking
effects. Whereas some of these aspects have been examined in
previous meta-and mega-analyses [10–12], this is, to our knowl-
edge, the most comprehensive patient-level post hoc analysis of
duloxetine to date. Likewise, it is the most extensive analysis yet
undertaken regarding possible differences between duloxetine
and the SSRIs with respect to response profile.
MATERIALS AND METHODS
Data acquisition and participants
Patient-level data for 15 drug company-sponsored, placebo-
controlled clinical trials regarding the treatment of depression in
adults with duloxetine and using the HDRS-17 for assessment of
efficacy were obtained from the Clinical Study Data Request
(CSDR) website; whereas 10 of these were named in the FDA
Approval Packages for duloxetine, five were post-marketing trials.
We confirmed that we had access to all relevant trials by searching
the FDA Approval Packages, the CSDR website, Eli Lilly’s Clinical
Study Results portal and Clinicaltrials.gov. For one trial named in
the FDA Approval Package, HMAG, data were not available. For
two of the trials, HMAH and HMAI, we only had access to
information regarding HDRS-17-sum and the items depressed
mood and suicidality; moreover, since these trials only included
sub-therapeutic doses (5–20mg), they were included in a
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sensitivity analysis only. While all remaining trials included adult
patients aged at least 18, two of them, HMBV and HMFA, included
elderly patients only and one, HMCB, only patients scoring a
minimum of two points on the Brief Pain Inventory scale. For the
comparison of duloxetine and the SSRIs with respect to item
response profile, we also used patient-level data from 28 drug
company-sponsored placebo-controlled trials of citalopram, par-
oxetine and sertraline; for details regarding this database, see ref.
[5]. Since some duloxetine studies were so designed that neither
patients nor investigators knew at which visit the administration
of active treatment started (double-blind variable lead-in),[13] 486
patients displayed HDRS-17 ratings below 15 points at the start of
active treatment. These were all retrospectively excluded by the
investigators in the original studies [14–20], and so also in our
primary analyses. In total, our primary analyses comprised
3575 subjects.
Statistical analysis
Linear mixed models including change score for the relevant
measure (HDRS-17-sum or individual items) as the dependent
variable, time (week), treatment (duloxetine or placebo), trial and
the treatment*time interaction as fixed factors, and baseline rating
for the corresponding outcome measure as covariate, were used
to assess the effect of treatment (duloxetine) on all included
outcome measures. For mean scores of the suicidality item, the
analysis comprising all subjects was complemented with analyses
undertaken after splitting the cohort into those 18–24 and those
≥25 years of age, respectively. The model described above was
expanded when assessing the possible interaction between HDRS-
17-rated baseline severity and treatment and when comparing the
relative efficacy of duloxetine to that of the SSRIs (see below).
ANCOVA models on the observed cases population were used
when addressing the association between side effects and
treatment efficacy (see below).
For all linear mixed models, an unstructured covariance matrix
was used to model within-patient errors; if the model did not
converge, an autoregressive heterogeneous structure was used
instead. Denominator degrees of freedom were estimated using
the Kenward-Roger approximation. Effect sizes were calculated by
dividing the least-squares mean differences for the relevant
contrast by the root of the variance for the corresponding
time point.
The possible relationship between baseline severity measured
by HDRS-17-sum and outcome was assessed using a model similar
to the one described above, but always including the baseline
score for HDRS-17-sum (rather than the baseline score of the
dependent variable) as well as the corresponding two-way
(baseline score*treatment, baseline score*time) and three-way
(baseline score*treatment*time) interactions. HDRS-17 sum,
depressed mood, the sum of six core symptoms of depression
(HDRS-6) [21] and the sum of the remaining 11 symptoms (non-
HDRS-6) served as effect parameters [22]. The outcome of interest
was the parameter estimates for the two-way interaction between
HDRS-17-sum rated baseline severity and treatment since this
parameter corresponds to the interaction effect at the endpoint
visit (week 8), which was the reference category. In addition,
patients at the extreme ends of the severity range, scoring ≤18
and ≥27 respectively, i.e. the lowest proposed cut-off for moderate
depression and the highest proposed for severe depression [23],
were compared with respect to baseline symptomatology and
with respect to endpoint effect sizes for HDRS-6, non-HDRS-6 and
all individual items.
Since a possible association between side effects and outcome
may be masked by patients with adverse events more often
discontinuing early, and by potential side effects of antidepres-
sants contaminating the HDRS-17-sum measure, the analysis
addressing this issue comprised completers only and used
depressed mood as effect parameter; a sensitivity analysis
replacing depressed mood with HDRS-17-sum is, however, also
presented. Presence of adverse events either during the first
2 weeks of treatment, or at any time until endpoint, was coded as
a dichotomous variable (yes/no) [24]. Adverse events that had
been reported already before the initiation of treatment were
excluded. The three groups thus compared, using analysis of
covariance (ANCOVA) with baseline values on the corresponding
outcome measure as covariate and trial as fixed factor, were
placebo-treated patients, duloxetine-treated patients with side
effects and duloxetine-treated patients without side effects. For
assessing the possible association between adverse event severity
and reduction in depressed mood, only duloxetine-treated
patients with adverse events were included, with the highest
side effect severity, coded as mild, moderate or severe, being
included in an ANCOVA as described above.
Finally, the item response profile of duloxetine was compared to
that of the SSRIs. To this end, patient-level data from the
duloxetine trials on the one hand, and patient-level data from
28 relevant drug company-sponsored trials conducted for
citalopram, paroxetine and sertraline [5] on the other, were used
to assess the relative effect size for each HDRS item using the sum
of all other HDRS items as covariate in two separate linear mixed
models. For these analyses week 6 served as endpoint since many
of the SSRI studies had been of only six weeks duration. In those of
the SSRI trials in which fluoxetine had been used as an active
comparator, this treatment arm was also included in the analyses.
Student’s t-test was used to compare subjects treated with
duloxetine and an SSRI, respectively, with regard to the relative
mean active drug versus placebo differences.
For all analyses, significance tests were two-tailed with an alpha
level of .05. No correction for multiple testing was undertaken.
Remote desktop access to the Clinical Trial Data Transparency
environment was provided by CSDR through SAS Solutions
OnDemand, using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Sensitivity analyses
To assess if the decision to exclude two low-dose trials impacted
the outcome, sensitivity analyses comprising all doses were
undertaken. Similarly, to explore the possible influence of
excluding patients scoring <15 points on the HDRS-17 at baseline,
sensitivity analyses including these patients were performed.
A final sensitivity analysis addressed the possible impact of side
effects on outcome using the HDRS-17-sum rather than depressed
mood as effect parameter. For all sensitivity analyses, the same
statistical models as in the corresponding main analysis
were used.
Ethics
The Regional Ethics Review Board of Gothenburg, Sweden, issued
an advisory opinion stating no objection to the conduct of
this study.
RESULTS
Effect sizes for individual items
Baseline characteristics for all included trials are displayed in
Supplementary table 1. Mean values of HDRS-17-sum and
depressed mood at baseline were 21.3 points (duloxetine: 21.3
points, placebo: 21.3 points) and 2.71 points (duloxetine: 2.71
points, placebo: 2.69 points), respectively. Effect sizes and levels of
significance for duloxetine with respect to HDRS-17-sum as well as
all individual items for weeks 1, 6 and 8 are presented in Table 1.
Three studies however lacked an evaluation at week 6 and 8; for
these observations, week 7 (HMCB) or week 9 (HMBHa+ b)
were used as endpoint observations, and week 5 (HMCB) or 7
(HMBHa+ b) as replacement for week 6 data. Week-for-week data
for HDRS-17-sum, depressed mood and psychic anxiety are
presented in Fig. 1a–c and for suicidality in Fig. 2a, b.
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The effect size for the comparison of duloxetine with placebo
was higher for depressed mood and psychic anxiety than for
HDRS-17-sum at all time points (Fig. 1a–c). A significant superiority
of duloxetine over placebo was found for the items depressed
mood, guilt, suicidality, agitation and psychic anxiety, but not for
HDRS-17-sum, at week one. Ratings of the items middle insomnia,
gastrointestinal symptoms, sexual dysfunction and loss of weight
were higher in duloxetine-treated patients after one week of
treatment but not at endpoint (Table 1). Analyses of the rating of
suicidality after splitting the population into those 18–24 or ≥25
years of age, respectively, yielded a significant superiority of
duloxetine from week one and onwards in those ≥ 25 years of age
(n= 3 318). In those 18–24 years of age (n= 257), patients on
duloxetine displayed numerically but non-significantly lower
ratings (Fig. 2a, b).
Relation between initial severity and outcome
The interaction between baseline severity based on HDRS-17-sum
and treatment was non-significant when using the HDRS-17-sum
(beta 0.10, standard error of the mean (SEM) 0.07, p= 0.11),
depressed mood (beta 0.01, SEM 0.01, p= 0.56) or the sum of 6
core symptoms of depression (beta 0.02, SEM 0.04, p= 0.50) as
outcome measure, but significant in the direction of larger drug-
placebo differences with increasing severity when analysing the
Table 1. Baseline means, effect sizes and p-values for HDRS-17-sum and individual items
Measure of efficacy (scoring range) Baseline mean s.d. ES p-value ES p-value ES p-value
Week 1 Week 6 Week 8
HDRS-17-sum 21.3 3.9 0.05 0.16 0.37 <0.001 0.37 <0.001
Depressed mood (0–4) 2.7 0.6 0.20 <0.001 0.46 <0.001 0.44 <0.001
Feelings of guilt (0–4) 1.6 0.8 0.10 0.004 0.27 <0.001 0.28 <0.001
Suicidal ideation (0–4) 0.6 0.8 0.15 <0.001 0.22 <0.001 0.23 <0.001
Insomnia, early (0–2) 1.2 0.8 0.05 0.14 0.06 0.18 0.09 0.02
Insomnia, middle (0–2) 1.3 0.8 −0.08 0.02 0.03 0.45 0.03 0.52
Insomnia, late (0–2) 1.1 0.8 −0.02 0.60 0.18 <0.001 0.13 0.001
Work & activities (0–4) 2.7 0.6 0.05 0.13 0.30 <0.001 0.32 <0.001
Retardation (0–4) 1.0 0.8 0.04 0.29 0.29 <0.001 0.22 <0.001
Agitation (0–4) 0.9 0.9 0.08 0.02 0.11 0.01 0.10 0.01
Anxiety, psychic (0–4) 2.0 0.8 0.23 <0.001 0.42 <0.001 0.43 <0.001
Anxiety, somatic (0–4) 1.5 0.8 -0.04 0.25 0.09 0.04 0.13 0.001
Somatic symptoms, gastrointestinal (0–2) 0.6 0.6 -0.30 <0.001 0.08 0.09 0.09 0.03
Somatic symptoms, general (0–2) 1.6 0.6 −0.02 0.66 0.25 <0.001 0.19 <0.001
Genital symptoms (0–2) 1.2 0.8 −0.10 0.004 0.05 0.29 0.10 0.01
Hypochondriasis (0–4) 1.0 0.9 0.04 0.27 0.22 <0.001 0.22 <0.001
Loss of weight (0–2) 0.2 0.5 −0.22 <0.001 −0.03 0.55 −0.05 0.19
Insight (0–2) 0.1 0.4 −0.05 0.15 0.04 0.34 0.07 0.07
s.d. standard deviation, ES effect size
Fig. 1 a–c Week-by-week mean change for HDRS-17-sum (a), the depressed mood item (b) and the psychic anxiety item (c) for duloxetine-
and placebo-treated subjects, respectively. Lines represent estimated means from a linear mixed model. Effect sizes at week 1, 2, 4, 6 and 8,
respectively: a 0.05, 0.20, 0.27, 0.37, 0.37; b 0.20, 0.31, 0.37, 0.46, 0.44 c; 0.23, 0.29, 0.34, 0.42, 0.43. n.s. non-significant (p= 0.16); ***= p < 0.001
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sum of the remaining 11 symptoms (beta 0.08, SEM 0.03, p= 0.02).
Baseline symptomatology and endpoint effect sizes for the
extreme severity groups (≤18 and ≥27, respectively) are presented
in Supplementary Table 2 and Supplementary Fig. 1a, b. While the
mean non-HDRS-6 sum score was 139% higher in the high severity
group, the HDRS-6 sum score was merely 63% higher. Likewise,
while the effect sizes for the HDRS-6 sum score and for individual
items comprising this subscale were similar in the two extreme
severity groups, the effect sizes for the sum score of the non-
HDRS-6 items, and for several of the items within this subscale,
were notably lower in the non-severe group.
Relation between side effects and outcome
Both duloxetine-treated patients not reporting early side effects
and those not reporting any side effects throughout the trial
displayed a significant reduction in depressed mood when
compared to those treated with placebo (Fig. 3a, b). This response
was moderately but significantly larger in those with side effects,
but there was no impact of side effect severity on outcome
(Supplementary Fig. 2).
Symptom response patterns in patients treated with duloxetine
or SSRIs
A comparison of all duloxetine-treated subjects with SSRI-treated
patients within the development programs for citalopram,
paroxetine and sertraline with respect to the relative reduction
of individual items after adjusting for overall response revealed
strikingly similar profiles, with no significant differences between
the groups (Fig. 4).
Sensitivity analyses
The outcome of the sensivity analyses for item-wise comparisons
of duloxetine versus placebo including also low-dose studies or
including all patients regardless of initial HDRS score were similar
to that of the main analyses (Supplementary tables 3 and 4,
respectively). The sensitivity analysis regarding the possible
relationship between side effects and outcome when using
HDRS-17-sum rather than depressed mood as outcome measure
yielded no influence of side effects on the response to treatment
(Supplementary Fig. 3a, b).
DISCUSSION
Based on trial-level meta-analyses using HDRS-17-sum as effect
parameter, oft-cited authors have claimed that the effect of
antidepressants is minute and clinically relevant, if at all, in cases
of severe depression only [1, 8]. However, invoking results from
patient-level, item-based post hoc analyses of placebo-controlled
trials, we have previously suggested the apparently poor effect of
the SSRIs to be an artefact caused by the use of a partly
misleading effect parameter; thus, when exploring the effect of
SSRIs on the depressed mood item, rather than on HDRS-17-sum,
a consistent and robust superiority of SSRIs over placebo was
revealed [5]. We now report the results of similar, patient-level,
item-based post hoc analyses of a non-SSRI antidepressant,
duloxetine, confirming this observation. Thus, in spite of other
methodological problems associated with antidepressant trials,
that should be expected to lead to an underrating of the efficacy
of the active drug [5, 25], the effect size for the reduction of
depressed mood obtained in the present analysis, 0.44, is in the
medium range and well on par with that displayed by drugs used
for somatic conditions [26] (and higher than that obtained for
HDRS-17-sum). Moreover, the beneficial effect of duloxetine was
not restricted to those with severe depression and not dependent
on side effects breaking the blind. A comparison of patients
treated with duloxetine and SSRIs, respectively, revealed a
strikingly similar item response pattern. The outcome of sensitivity
analyses including also low-dose studies or patients with low
baseline scores was essentially the same as that of the main
analyses.
The previous claim that antidepressants be ineffective in mild
and moderate cases [1] has prompted authorities in many
countries to recommend non-pharmacological treatment for
non-severe depression. Our analysis, however, revealed the
duloxetine-induced reduction in depressed mood and other core
symptoms of depression in patients at the lower end of the
severity spectrum to be largely on par with that observed in the
most severe cases; in line with this, no significant interaction
between baseline severity and treatment was observed when
addressing outcome using these measures. For the reduction in
HDRS-17-sum, however, a non-significant tendency for an
influence of severity on response was observed, which can largely
Fig. 2 a, b Week-by-week mean change for the suicidality item for duloxetine and placebo-treated subjects, respectively, in subjects aged 25
years and above (a) subjects aged 18–24 years (b). Lines represent estimated means from a linear mixed model. Baseline scores a 0.62 points,
standard deviation (SD) 0.76; b 0.53 points, SD 0.70. Effect sizes at week 1, 2, 4, 6 and 8, respectively: a 0.15, 0.23, 0.26, 0.23, 0.24; b 0.22, 0.22,
0.13, 0.25, 0.20. n.s. non-significant (p= 0.10, 0.11, 0.42, 0.16, 0.21); ***p < 0.001
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be explained by lower effect sizes for non-core symptoms in the
non-severe group; thus, the effect size for the sum of the non-core
items was indeed significantly associated with baseline severity.
When interpreting this observation, it should be noted that the
rating of non-core symptoms of depression, considerably more so
than that of core symptoms, often was low or zero at baseline in
cases defined as non-severe, hence leaving little room for
improvement, but ample room for aggravation also in patients
in remission should the item capture possible side effects of the
given treatment. We hence suggest that the widely disseminated
claim that antidepressants are useless for non-severe depression is
misleading and the result of the unfortunate use of an outcome
measure comprising many items that are often absent at baseline
in the non-severe group. Though not comprising any interaction
analyses corresponding to those here reported, a previous report
from Shelton and co-workers [12], based on post hoc analyses of
four duloxetine trials, was largely in line with our findings.
Another widely propagated claim aimed to cast doubt on the
usefulness of antidepressants is that the superiority of active drug
over placebo observed in antidepressant trials be merely a
consequence of enhanced expectation of improvement due to
side-effects breaking the blind [9]. The finding that the effect size
for the reduction in depressed mood (unlike that for the reduction
in HDRS-17-sum) was somewhat larger in duloxetine-treated
patients reporting side effects than in those not reporting side
effects could be regarded as support for this assumption; needless
to say, this association may, however, also be the consequence of
inter-individual differences in dose and/or duloxetine metabolism
that, by influencing serum levels, may impact both response
and side effects in the same direction. More importantly,
the theory that side effects are the major factor for active
treatment outperforming placebo was rebutted by the
observation of a marked superiority of duloxetine over placebo
also in patients reporting no adverse events. Likewise, no support
was obtained for the suggestion by Kirsch that adverse event
severity be positively associated with response [9]. Both the latter
observations are in line with what we previously reported for two
SSRIs [24].
Attempts to reveal the mechanism of action of SSRIs and SNRIs,
beyond the inhibition of transmitter reuptake, have often been
based on the postulate that no clinical effect is observed until the
treatment has been ongoing for a number of weeks [27]. However,
the failure to detect an early effect of drug treatment using the
HDRS-17-sum may be due to early side-effects of treatment
contaminating the rating, hence masking an early improvement
with respect to core symptoms of depression such as depressed
mood [5, 6]. In this vein, while there was no difference between
treatment groups with respect to HDRS-17-sum at week 1,
duloxetine-treated patients reported less severity with respect to
several cardinal symptoms of depression already at this time
point, including depressed mood, but significantly more middle
insomnia, gastrointestinal symptoms, sexual dysfunction and loss
of weight. We hence gained support for our previous conclusion,
based on similar post hoc analyses of SSRI trials [6], that the
antidepressant action of amine reuptake inhibitors, though slow
to reach its maximum, does commence shortly after the onset of
treatment. Our results are also in line with previous reports
suggesting duloxetine to outperform placebo with respect to
individual items already at week 1 [12, 27], as well as with a report
on the use of venlafaxine in generalised anxiety disorder
indicating early side effects to mask an early improvement with
respect to certain symptoms (including anxiety) [28].
Antidepressants displaying high affinity for the serotonin
transporter, such as clomipramine and the SSRIs, may cause an
Fig. 3 a, b Estimated endpoint means and effect sizes for the depressed mood item in placebo-treated subjects and in duloxetine-treated
subjects with or without adverse events a only counting initial adverse events (reported during week 1–2 and b counting any adverse event
throughout the trial. Placebo: n= 998; duloxetine without early adverse events: n= 713; duloxetine with early adverse events: n= 1 029;
duloxetine without any adverse event throughout the trial: n= 449; duloxetine with any adverse event throughout the trial: n= 1 293. Effect
sizes: a duloxetine with adverse events vs placebo: 0.46; duloxetine without adverse events vs placebo: 0.34, duloxetine with adverse events vs
duloxetine without adverse events: 0.12 b duloxetine with adverse events vs placebo: 0.44: duloxetine without adverse events vs placebo:
0.36; duloxetine with adverse events vs duloxetine without adverse events: 0.12. *p= 0.02 (a), p= 0.04 (b); ***p < 0.001
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initial increase in anxiety in susceptible patients [29, 30]. Our
previous attempt to clarify the early net effect of SSRIs on HDRS-
17-assessed anxiety revealed psychic anxiety and agitation to be
moderately lower, but somatic anxiety to be moderately higher,
after the first week of treatment in those administered an SSRI
[31]. The corresponding outcome for duloxetine was well in line
with that observed for the SSRIs: a significant reduction in psychic
anxiety and agitation but not in somatic anxiety at week 1 [11].
However, while the rating of somatic anxiety at week 1 was
numerically higher for duloxetine-treated patients, this difference
was not significant, as It was for the SSRIs. At week 6 and at
endpoint, all three items were in favour of duloxetine. It should,
however, be noted that a complete picture of a possible anxiety-
provoking effect of an antidepressant requires an analysis also of
the reporting of anxiety-related adverse events [31], particularly in
patients discontinuing before the week 1 visit, and that no such
assessment was included in this study.
Reports suggesting SSRIs to be suicide-provoking, and particu-
larly so at the start of treatment [32] and in young subjects [33],
have previously prompted us [34] and others [35] to address this
issue by analysing HDRS-17-assessed suicidality at the week one
visit following initiation of treatment after splitting the population
into young adults and adults, respectively. While these previous
studies have shown SSRIs [34, 35], as well as an SNRI, venlafaxine
[35], to cause a net reduction in suicidality from week 1 or 2 and
onwards in subjects ≥25 years of age, they have failed to
demonstrate a corresponding effect in subjects below the age of
25, but also without providing any evidence of a suicidality-
enhancing effect in this age group. A previous comprehensive
post hoc analysis regarding the possible impact of duloxetine on
self-rated suicidal ideation suggested the net effect of the drug on
the suicidality item of the HDRS to be beneficial, but did not
specifically address the issue of possible early effects or age [10].
The present results were similar to those previously obtained for
SSRIs and venlafaxine; the mean rating of suicidality in duloxetine-
treated subjects compared to those on placebo was hence
significantly lower in subjects ≥25 years already from week one
and onwards. In the younger age group, a corresponding
superiority of duloxetine was also at hand from week one and
onwards, but never reached the level of statistical significance;
when interpreting this difference between the two age groups, it
should, however, be noted that the number of subjects aged
18–24 was much lower (n= 257) than that of the older subjects (n
= 3318). While these data do not exclude the possibility that
duloxetine may exert a paradoxical suicide-provoking effect in
susceptible individuals, they lend no support for the assumption
that the net effect of the drug on suicidality, at the first week of
treatment or at endpoint, be harmful, either in those below or
above the age of 25. Since no children or adolescents were
included, our data, however, permit no conclusions with respect
to the possible effect of duloxetine on suicidality in these age
groups.
Duloxetine displaying affinity not only for the transporter of
serotonin, but also for that of noradrenaline [7], has prompted
previous writers to suggest that this drug displays a somewhat
different response profile as compared to that of the SSRIs. In line
with this, a previous post hoc analysis from Mallinckrodt and co-
workers, based on six trials comprising a duloxetine arm, an SSRI
arm and placebo, suggested duloxetine to outperform the SSRIs
with respect to a number of items (work and activities,
psychomotor retardation, genital symptoms and hypochondriasis)
[36]. To some extent, the interpretation of the outcome of these
head-to-head comparisons is, however, marred by the fact that
the SSRI dose applied in three of them, as acknowledged by the
Fig. 4 Relative effect sizes versus placebo for duloxetine and four SSRIs (grouped) using the sum of all other HDRS-17 items as covariate.
Placebo (duloxetine studies): n= 1 345; duloxetine: n= 2 230; placebo (SSRI studies): n= 2 581; SSRIs: n= 5 681 (citalopram n= 744; fluoxetine
n= 754; paroxetine n= 2 981; sertraline n= 1 202). HDRS-17 items and p-values for the contrast duloxetine vs SSRIs: 1= depressed mood (p=
0.63), 2= feelings of guilt (p= 0.35), 3= suicidality (p= 0.89), 4= early insomnia (p= 0.59), 5=middle insomnia (p= 0.59), 6= late insomnia
(p= 0.24), 7=work & activities (p= 0.82), 8= psychomotor retardation (p= 0.49), 9= psychomotor agitation (p= 0.26), 10= psychic anxiety
(p= 0.65), 11= somatic anxiety (p= 0.93), 12= gastrointestinal symptoms (p= 0.23), 13= general somatic symptoms (p= 0.39), 14= sexual
dysfunction (p= 0.54), 15= hypochondriasis (p= 0.45), 16=weight change (p= 0.80) and 17= insight (p= 0.78)
Item-based analysis of the effects of duloxetine in depression: a. . .
A Lisinski et al.
558
Neuropsychopharmacology (2020) 45:553 – 560
authors, may have been suboptimal [37, 38]. We hence used a
different path to explore the same issue, i.e. to compare the
relative item response profile (after adjustment for overall
response) of the duloxetine-treated patients included in the
dataset on which this paper is based with that of the SSRI-treated
patients included in the development programs for citalopram,
paroxetine and sertraline (n= 8262) [5]. This analysis revealed a
strikingly similar response profile for the SSRIs and duloxetine,
respectively, hence arguing against any major differences
between these two treatments. While it should be underlined
that adequately powered head-to-head trials using equipotent
doses are required to definitely settle the issue of possible
differences in efficacy or effect profile between two treatments,
this lack of apparent differences in response profile is somewhat
surprising; since duloxetine but not the SSRIs is reported to inhibit
the noradrenaline transporter (NET), certain dissimilarities in
clinical response profile might indeed have been expected. One
possible explanation to this similarity of SSRIs and an SNRI,
respectively, could be that the influence of duloxetine on NET in
the human brain at the dosage used to treat depression may be
lower than usually assumed; recent positron emission tomography
studies thus indicate that duloxetine at clinically relevant dosage
blocks less than 40% of NET but around 80% of the serotonin
transporter (SERT) [39]. It is also possible that the contribution of
additional NET inhibition to an antidepressant response obtained
by SERT inhibitors has been overrated, and/or that the response
pattern observed reflects the nature of the disorder rather than of
the given treatment, i.e. that a similar response profile should be
expected for any effective antidepressant regimen when com-
pared to placebo. Similar studies comparing the response profile
of SSRIs and duloxetine with that of antidepressants not
influencing SERT or NET might shed further light on this issue.
Finally, when interpreting the present data, it should be
considered that there may indeed exist differences between
duloxetine and SSRIs that are not captured by any of the HDRS-17
items; duloxetine has, for example, been attributed superior
efficacy for the treatment of pain [40], which is an effect that is not
necessarily reflected by the HDRS-17.
The present analysis differs from the majority (though not all) of
previous meta-analyses in the antidepressant field by being
conducted on patient- rather than trial-level, and by analysing
individual symptoms rather than the sum score of several items.
We believe that such an approach, which is in line with the RDoC
focus on symptoms and dimensions rather than diagnoses [41], to
be particularly useful when analysing a condition such as
depression, where patients differ considerably with respect to
symptom profile at baseline. Of note is that a number of widely
spread assumptions regarding the antidepressant drugs, such as
their symptom-reducing effect being secondary to side effects [9],
or the antidepressant effect being restricted to those with severe
depression [1, 8], were based on trial-level, HDRS-17-sum-based
meta-analyses, which have, however, now been rebutted by
analyses conducted on the patient level [22] and/or being item-
based [24, 42] (including the present one).
To conclude, item-based analyses of duloxetine trials revealed
this drug to exert a robust reduction in depressed mood and other
core symptoms of depression that, for several of these, was
significant already after 1 week of treatment. The effect of
duloxetine was not restricted to those with high HDRS-17-sum at
baseline and not secondary to side effects; moreover, no support
for a suicide-provoking effect was obtained. Comparisons of the
effect profiles of duloxetine and SSRIs, respectively, revealed a
strikingly similar picture.
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